Researchers at the Icahn School of Medicine at Mount Sinai have developed a first-of-its-kind mRNA system that switches on therapeutic genes preferentially inside targeted cells—an advance ...

The FDA has approved lerodalcibep-liga, a third-generation injectable PCSK9 inhibitor, to reduce LDL cholesterol in adults ...

Lerodalcibep-liga, a once-monthly PCSK9 inhibitor, significantly reduces LDL-C in hypercholesterolemia, including HeFH, with ...

Antibody treatments for cancer and other diseases are typically delivered intravenously, because of the large volumes that are needed per dose. This means the patient has to go to a hospital for every ...

We analyzed ten online NAD+ platforms and outlined the crucial characteristics for you. Take a look at the platforms that check the most important boxes.

Research reveals that silica scaffolds can train the immune system against S. aureus, offering a novel approach to prevent ...

“With today’s approval, guselkumab is the first IL-23 inhibitor to offer inflammatory bowel disease patients robust clinical and endoscopic results with a fully subcutaneous induction dose regimen, ...

Injecting a fatty acid that is used to make very long fat molecules into the eyes of elderly mice improved their vision for up to a month, indicating that the natural compound could potentially be ...

The FDA approved a subcutaneous formulation of the blockbuster cancer drug pembrolizumab (Keytruda Qlex) for use across the drug's numerous solid tumors indications. The new formulation combines ...

Compared with placebo, significantly greater proportions of patients treated with Tremfya achieved clinical remission and endoscopic improvement. HealthDay News — The US Food and Drug Administration ...

Merck (NYSE:MRK) said that the FDA has cleared Keytruda Qlex, a new subcutaneous version of its blockbuster cancer drug, offering a faster alternative to IV infusion, a company spokesperson confirmed ...